The Current Drug Discovery Landscape for Chagas Disease, HAT and Leishmaniasis: Target Validation and Chemotherapy
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (20 April 2024) | Viewed by 1297
Special Issue Editor
Special Issue Information
Dear Colleagues,
We are pleased to release the new Special Issue of Pharmaceuticals, entitled “The Current Drug Discovery Landscape for Chagas Disease, HAT and Leishmaniasis: Target Validation and Chemotherapy”. Our focus on these neglected tropical diseases (NTDs) is motivated by the limited therapeutic options available for their treatment, a state which persists despite the high impact of these diseases worldwide. Limited treatment efficacy, parasite resistance, and severe adverse effects are some of the problems which must be overcome by novel treatments.
Over the past years, public–private partnerships and academic consortiums have developed drug candidates and brought new therapies to the populations affected by NTDs. Examples from the past five years include the approval of Fexinidazole as a novel orally available for treating HAT caused by T. b. gambiense, and the successful treatment of patients with visceral leishmaniasis using a combination of miltefosine and paromomycin. Nevertheless, unmet needs remain. There are still no drugs which are effective in the chronic stage of Chagas disease, with very few drug candidates under consideration, and a similar scenario can be observed for cutaneous and mucocutaneous leishmaniasis.
Given the importance of developing novel therapies for Chagas disease, HAT, and leishmaniasis, we welcome authors to submit studies to this Special Issue and report on potential new drug candidates or contribute to the characterization and validation of molecular targets. Authors should contribute with their most recent results, or with reviews related to these topics. We look forward to receiving your contribution.
Prof. Dr. Rafaela Salgado Ferreira
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- kinetoplastids
- drug discovery
- molecular targets
- Chagas disease
- human African trypanosomiasis
- leishmaniasis
